Physician profile
Leonard Esward Philo
NPI 1396893699
$4,550.56
in general payments reported to CMS, 2019-2025
28 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2021: $210 · 2023: $234 · 2024: $2,090 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,061 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,061.45 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.71 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $562.85 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $436.09 | 2024-2025 | Entyvio, Eohilia |
| Pfizer INC. | $375.47 | 2024-2025 | |
| Genzyme Corporation | $270.49 | 2024-2025 | |
| Janssen Biotech, INC. | $262.40 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $228.98 | 2019-2024 | Captivator II |
| Veloxis Pharmaceuticals, INC. | $210.28 | 2021 | |
| Janssen Scientific Affairs, LLC | $198.95 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $137.90 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $123.96 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $116.55 | 2019 | |
| Conmed Corporation | $108.33 | 2025 | Airseal |
| Qol Medical, LLC | $99.41 | 2025 | Sucraid |
| Celgene Corporation | $91.57 | 2024 | Zeposia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $75.36 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $67.81 | 2025 | Zenpep, Vowst |
| Organon LLC | $62.77 | 2023-2025 | Hadlima, Renflexis |
| Madrigal Pharmaceuticals | $56.10 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.38 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $44.46 | 2023-2024 | Dificid |
| Enterra Medical, INC. | $37.57 | 2025 | |
| Gilead Sciences, INC. | $30.22 | 2024 | |
| Daiichi Sankyo INC. | $29.54 | 2024 | Injectafer |
| Braintree Laboratories, INC. | $27.94 | 2024 | Sutab |
| Intuitive Surgical, INC. | $21.62 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $20.06 | 2025 | Dupixent |
| Novo Nordisk INC | $14.79 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Philo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.